The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Tay-Sachs Disease

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Tay-Sachs Disease

 

High impact information on Tay-Sachs Disease

  • We developed methods to detect the three mutations in the HEXA gene that occur with high frequency among Ashkenazi Jews: two mutations cause infantile Tay-Sachs disease, and the third causes the adult-onset form of the disease [6].
  • A test for the mutant allele based on amplification of DNA by the 'polymerase chain rection and cleavage of a DdeI restriction site generated by the mutation revealed that this case and two other cases of the Ashkenazi, infantile form of Tay-Sachs disease are heterozygous for two different mutations [7].
  • A strategy for the treatment of these diseases, based on an inhibitor of GSL biosynthesis N-butyldeoxynojirimycin, was evaluated in a mouse model of Tay-Sachs disease [8].
  • Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease [9].
  • Tay-Sachs disease in Moroccan Jews: deletion of a phenylalanine in the alpha-subunit of beta-hexosaminidase [10].
 

Chemical compound and disease context of Tay-Sachs Disease

  • Two Tay-Sachs disease (TSD) patients of French-Canadian origin were shown by Myerowitz and Hogikyan to be homozygous for a 7.6-kb deletion mutation at the 5' end of the hexosaminidase A alpha-subunit gene [11].
  • Active arginine residues in beta-hexosaminidase. Identification through studies of the B1 variant of Tay-Sachs disease [12].
  • A glycine250--> aspartate substitution in the alpha-subunit of hexosaminidase A causes juvenile-onset Tay-Sachs disease in a Lebanese-Canadian family [13].
  • The search for the genetic lesion in Ashkenazi Jews with Classic Tay-Sachs disease [14].
  • In the course of defining mutations causing Tay-Sachs disease (TSD) in non-Jewish patients and carriers from the British Isles, we identified a guanine to adenine change (also previously described) in the obligatory GT sequence of the donor splice site at the 5' end of intron 9 of the hexosaminidase alpha peptide gene [15].
 

Biological context of Tay-Sachs Disease

 

Anatomical context of Tay-Sachs Disease

 

Gene context of Tay-Sachs Disease

  • Common HEXB polymorphisms reduce serum HexA and HexB enzymatic activities, potentially masking Tay-Sachs disease carrier identification [25].
  • Disruption of the Hexa gene encoding the alpha-subunit of Hex has led to the generation of a mildly affected mouse model of human Tay-Sachs disease, allowing us the opportunity to analyze the effects of isolated Hex A deficiency on epithelial cellular morphology of the male reproductive tract [26].
  • No carriers of Tay-Sachs disease (56 screened), Gaucher disease (32 screened), Canavan disease (22 screened) or the BRCA1 185delAG mutation (22 screened) were found [27].
  • This outcome confirmed the reversibility of GM2 accumulation and opens the way to pharmacological induction or activation of sialidase for the treatment of human Tay-Sachs disease [28].
  • We performed a genetic epidemiological analysis of American non-Jewish people with ancestry from Ireland or Great Britain with regard to heterozgosity for Tay-Sachs disease (TSD) [29].
 

Analytical, diagnostic and therapeutic context of Tay-Sachs Disease

References

  1. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Huang, J.Q., Trasler, J.M., Igdoura, S., Michaud, J., Hanal, N., Gravel, R.A. Hum. Mol. Genet. (1997) [Pubmed]
  2. The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease. Maier, T., Strater, N., Schuette, C.G., Klingenstein, R., Sandhoff, K., Saenger, W. J. Mol. Biol. (2003) [Pubmed]
  3. Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: genetic drift as a robust and parsimonious hypothesis. Frisch, A., Colombo, R., Michaelovsky, E., Karpati, M., Goldman, B., Peleg, L. Hum. Genet. (2004) [Pubmed]
  4. Strategies to respond to polymerase chain reaction deoxyribonucleic acid amplification failure in a preimplantation genetic diagnosis program. Gibbons, W.E., Gitlin, S.A., Lanzendorf, S.E. Am. J. Obstet. Gynecol. (1995) [Pubmed]
  5. Specificity and sensitivity of hexosaminidase assays and DNA analysis for the detection of Tay-Sachs disease gene carriers among Ashkenazic Jews. Fernandes, M.J., Kaplan, F., Clow, C.L., Hechtman, P., Scriver, C.R. Genet. Epidemiol. (1992) [Pubmed]
  6. Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. Triggs-Raine, B.L., Feigenbaum, A.S., Natowicz, M., Skomorowski, M.A., Schuster, S.M., Clarke, J.T., Mahuran, D.J., Kolodny, E.H., Gravel, R.A. N. Engl. J. Med. (1990) [Pubmed]
  7. Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Arpaia, E., Dumbrille-Ross, A., Maler, T., Neote, K., Tropak, M., Troxel, C., Stirling, J.L., Pitts, J.S., Bapat, B., Lamhonwah, A.M. Nature (1988) [Pubmed]
  8. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Platt, F.M., Neises, G.R., Reinkensmeier, G., Townsend, M.J., Perry, V.H., Proia, R.L., Winchester, B., Dwek, R.A., Butters, T.D. Science (1997) [Pubmed]
  9. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Yamanaka, S., Johnson, M.D., Grinberg, A., Westphal, H., Crawley, J.N., Taniike, M., Suzuki, K., Proia, R.L. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  10. Tay-Sachs disease in Moroccan Jews: deletion of a phenylalanine in the alpha-subunit of beta-hexosaminidase. Navon, R., Proia, R.L. Am. J. Hum. Genet. (1991) [Pubmed]
  11. More than one mutant allele causes infantile Tay-Sachs disease in French-Canadians. Hechtman, P., Kaplan, F., Bayleran, J., Boulay, B., Andermann, E., de Braekeleer, M., Melançon, S., Lambert, M., Potier, M., Gagné, R. Am. J. Hum. Genet. (1990) [Pubmed]
  12. Active arginine residues in beta-hexosaminidase. Identification through studies of the B1 variant of Tay-Sachs disease. Brown, C.A., Mahuran, D.J. J. Biol. Chem. (1991) [Pubmed]
  13. A glycine250--> aspartate substitution in the alpha-subunit of hexosaminidase A causes juvenile-onset Tay-Sachs disease in a Lebanese-Canadian family. Trop, I., Kaplan, F., Brown, C., Mahuran, D., Hechtman, P. Hum. Mutat. (1992) [Pubmed]
  14. The search for the genetic lesion in Ashkenazi Jews with Classic Tay-Sachs disease. Myerowitz, R. Adv. Genet. (2001) [Pubmed]
  15. Beta-hexosaminidase splice site mutation has a high frequency among non-Jewish Tay-Sachs disease carriers from the British Isles. Landels, E.C., Green, P.M., Ellis, I.H., Fensom, A.H., Bobrow, M. J. Med. Genet. (1992) [Pubmed]
  16. A novel mechanism for desulfation of mucin: identification and cloning of a mucin-desulfating glycosidase (sulfoglycosidase) from Prevotella strain RS2. Rho, J.H., Wright, D.P., Christie, D.L., Clinch, K., Furneaux, R.H., Roberton, A.M. J. Bacteriol. (2005) [Pubmed]
  17. Preimplantation genetic diagnosis for Tay-Sachs disease: successful pregnancy after pre-embryo biopsy and gene amplification by polymerase chain reaction. Gibbons, W.E., Gitlin, S.A., Lanzendorf, S.E., Kaufmann, R.A., Slotnick, R.N., Hodgen, G.D. Fertil. Steril. (1995) [Pubmed]
  18. First trimester prenatal diagnosis of Tay-Sachs disease using the sulfated synthetic substrate for hexosaminidase A. Callahan, J.W., Archibald, A., Skomorowski, M.A., Shuman, C., Clarke, J.T. Clin. Biochem. (1990) [Pubmed]
  19. Hexosaminidase A analysis of various biological fluids by pH inactivation for the identification of Tay-Sachs disease genotypes. Saifer, A., Perle, G. Prog. Clin. Biol. Res. (1977) [Pubmed]
  20. Diagnosis and carrier detection of Tay-Sachs disease: direct determination of hexosaminidase A using 4-methylumbelliferyl derivatives of beta-N-acetylglucosamine-6-sulfate and beta-N-acetylgalactosamine-6-sulfate. Ben-Yoseph, Y., Reid, J.E., Shapiro, B., Nadler, H.L. Am. J. Hum. Genet. (1985) [Pubmed]
  21. Tay-Sachs disease: ultrastructural studies on cultured fibroblasts. Wyatt, P.R., Cox, D.M., Hoogstraten, J. Pediatr. Res. (1978) [Pubmed]
  22. Molecular forms of beta-N-acetylhexosaminidase in Epstein-Barr virus-transformed lymphoid cell lines from normal subjects and patients with Tay-Sachs disease. Salvayre, R., Maret, A., Negre, A., Lenoir, G., Vuillaume, M., Icart, J., Didier, J., Douste-Blazy, L. Eur. J. Biochem. (1983) [Pubmed]
  23. Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system. Miklyaeva, E.I., Dong, W., Bureau, A., Fattahie, R., Xu, Y., Su, M., Fick, G.H., Huang, J.Q., Igdoura, S., Hanai, N., Gravel, R.A. Brain Res. (2004) [Pubmed]
  24. Enzyme replacement treatment for Tay-Sachs disease brain cells in culture utilizing concanavalin A-mediated hexosaminidase A uptake: biochemical and morphological evidence of GM2 mobilization. Brooks, S.E., Hoffman, L.M., Adachi, M., Amsterdam, D., Schneck, L. Acta Neuropathol. (1980) [Pubmed]
  25. Common HEXB polymorphisms reduce serum HexA and HexB enzymatic activities, potentially masking Tay-Sachs disease carrier identification. Vallance, H., Morris, T.J., Coulter-Mackie, M., Lim-Steele, J., Kaback, M. Mol. Genet. Metab. (2006) [Pubmed]
  26. II. Characterization and development of the regional- and cellular-specific abnormalities in the epididymis of mice with beta-hexosaminidase A deficiency. Adamali, H.I., Somani, I.H., Huang, J.Q., Gravel, R.A., Trasler, J.M., Hermo, L. J. Androl. (1999) [Pubmed]
  27. Screening semen donors for hereditary diseases. The Fairfax cryobank experience. Bick, D., Fugger, E.F., Pool, S.H., Hazelrigg, W.B., Yadvish, K.N., Spence, W.C., Maddalena, A., Howard-Peebles, P.N., Schulman, J.D. The Journal of reproductive medicine. (1998) [Pubmed]
  28. Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells. Igdoura, S.A., Mertineit, C., Trasler, J.M., Gravel, R.A. Hum. Mol. Genet. (1999) [Pubmed]
  29. Heterozygosity for Tay-Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain. van Bael, M., Natowicz, M.R., Tomczak, J., Grebner, E.E., Prence, E.M. J. Med. Genet. (1996) [Pubmed]
  30. Beta-N-acetylhexosaminidase activity in human oocytes and preimplantation embryos. Sermon, K., Lissens, W., Tarlatzis, B., Braude, P.R., Devroey, P., Van Steirteghem, A., Liebaers, I. Hum. Reprod. (1992) [Pubmed]
  31. Prenatal diagnosis of Tay-Sachs disease: studies on the reliability of hexosaminidase levels in amniotic fluid. Grebner, E.E., Jackson, L.G. Am. J. Obstet. Gynecol. (1979) [Pubmed]
  32. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry as a rapid screening method to detect mutations causing Tay-Sachs disease. Srinivasan, J.R., Liu, Y.H., Venta, P.J., Siemieniak, D., Killeen, A.A., Zhu, Y., Lubman, D.M. Rapid Commun. Mass Spectrom. (1997) [Pubmed]
 
WikiGenes - Universities